Esperion Therape Stock Price, News & Analysis

Esperion reported a strong performance for Q4 2021, with U.S. net product revenue for NEXLETOL and NEXLIZET growing 12% sequentially to $12.2 million, a 200% increase for the full year. Prescriptions rose by 9%, reaching approximately 70,000 patients. The company strengthened its capital position with $209 million from equity financing, extending its cash runway to support the upcoming CLEAR Outcomes trial results.

Esperion anticipates significant operating expenses in 2022, with R&D expenses projected between $100 million to $110 million.

Esperion (NASDAQ: ESPR) will announce its fourth quarter and full year 2021 financial results on February 22, 2022, before the U.S. market opens. The company will conduct a webcast and conference call at 8:00 a.m. ET to discuss the results and business progress, accessible via phone or on their website. Esperion focuses on innovating cholesterol-lowering medications, including NEXLETOL® and NEXLIZET® tablets, aimed primarily at patients inadequately served by existing treatments.

Esperion (NASDAQ: ESPR) granted stock options and restricted stock units (RSUs) to four new employees on January 27, 2022. Notably, Benjamin Looker, the new General Counsel, received options to purchase 100,450 shares at an exercise price of $3.65 per share and 70,800 RSUs. The RSUs will vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly. This granting aligns with the 2017 Inducement Equity Incentive Plan, aimed at attracting new talent to the company, which focuses on innovative cholesterol-lowering therapies.

Esperion (NASDAQ: ESPR) announced preliminary Q4 2021 net U.S. product revenue estimated between $12.0 and $12.5 million. The company maintains its full-year 2022 operating expense guidance at $220 million to $240 million, inclusive of $25 million in non-cash stock-compensation expenses. A significant milestone is the ongoing CLEAR Outcomes Trial, achieving 85% major adverse cardiac events (MACE) accumulation by December 2021. The company will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022.

Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will present at the J.P. Morgan 40th Annual Healthcare Conference on January 13, 2022, at 10:30 a.m. ET. The presentation will include a live audio webcast available on the company's investor relations website, with replays archived for 90 days. Esperion focuses on lipid management, developing innovative medicines to lower cholesterol for patients underserved by existing solutions. More details can be found at www.esperion.com.

Esperion has appointed Benjamin O. Looker as general counsel effective January 1, 2022. Looker brings extensive experience from his previous roles in the pharmaceutical industry, including serving as general counsel at Trillium Therapeutics. His expertise will be critical as Esperion approaches significant milestones, particularly the completion of the CLEAR Outcomes trial and the development of its early-stage pipeline. The leadership believes Looker's guidance will enhance the company's legal, compliance, and ethics operations.

Esperion (NASDAQ: ESPR) has successfully closed its public offering of 32,142,858 shares of common stock and warrants, raising approximately $225 million in gross proceeds. After expenses, net proceeds total around $208.8 million. The underwriter has also partially exercised a 30-day option for additional warrants. The funds will support the commercialization of NEXLETOL and NEXLIZET, as well as research and development efforts. The offering was conducted under a previously filed shelf registration statement with the SEC.

Esperion (NASDAQ: ESPR) has announced a public offering of 32,142,858 shares of common stock, alongside short-term warrants for the same amount, priced at $7.00 each. The offering, set to close on or around December 7, 2021, is expected to generate approximately $225 million in gross proceeds. These funds will be used for commercialization of NEXLETOL and NEXLIZET, pipeline development, and general corporate purposes. The underwriter, H.C. Wainwright & Co., has a 30-day option to purchase an additional 4,821,428 shares or warrants.

Esperion (NASDAQ: ESPR) announced its plan to conduct an underwritten public offering of common stock and warrants, subject to market conditions. The company aims to use the net proceeds for the commercialization of NEXLETOL and NEXLIZET, along with research and development for its pipeline. H.C. Wainwright & Co. will serve as the sole book-running manager for this offering. The offering is subject to various conditions, with no guarantee on its completion or terms. A registration statement has been filed with the SEC, and additional details will be available in a related prospectus.